DBV Technologies SA
PAR:DBV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
DBV Technologies SA
Accrued Liabilities
DBV Technologies SA
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
DBV Technologies SA
PAR:DBV
|
Accrued Liabilities
$14.3m
|
CAGR 3-Years
34%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
11%
|
|
|
Valneva SE
PAR:VLA
|
Accrued Liabilities
€35m
|
CAGR 3-Years
31%
|
CAGR 5-Years
22%
|
CAGR 10-Years
18%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Accrued Liabilities
€3k
|
CAGR 3-Years
-91%
|
CAGR 5-Years
-77%
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Accrued Liabilities
€5.5m
|
CAGR 3-Years
19%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Cellectis SA
PAR:ALCLS
|
Accrued Liabilities
$10.8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
10%
|
|
|
Abivax SA
PAR:ABVX
|
Accrued Liabilities
€4.7m
|
CAGR 3-Years
27%
|
CAGR 5-Years
19%
|
CAGR 10-Years
18%
|
|
DBV Technologies SA
Glance View
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, Ile-De-France. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
See Also
What is DBV Technologies SA's Accrued Liabilities?
Accrued Liabilities
14.3m
USD
Based on the financial report for Dec 31, 2025, DBV Technologies SA's Accrued Liabilities amounts to 14.3m USD.
What is DBV Technologies SA's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
11%
Over the last year, the Accrued Liabilities growth was 91%. The average annual Accrued Liabilities growth rates for DBV Technologies SA have been 34% over the past three years , -4% over the past five years , and 11% over the past ten years .
